Skip to main content
Top
Published in: Journal of the International AIDS Society 1/2010

Open Access 01-12-2010 | Research

High rate of loss to clinical follow up among African HIV-infected patients attending a London clinic: a retrospective analysis of a clinical cohort

Authors: Sarah M Gerver, Tim R Chadborn, Fowzia Ibrahim, Bela Vatsa, Valerie C Delpech, Philippa J Easterbrook

Published in: Journal of the International AIDS Society | Issue 1/2010

Login to get access

Abstract

Background

Long-term regular clinic follow up is an important component of HIV care. We determined the frequency and characteristics of HIV-infected patients lost to follow up from a London HIV clinic, and factors associated with loss to all HIV follow up in the UK.

Methods

We identified 1859 HIV-infected adults who had registered and attended a London clinic on one or more occasions between January 1997 and December 2005. Loss to follow up was defined as clinic non-attendance for one or more years. Through anonymized linkage with the Survey of Prevalent HIV Infections Diagnosed and Health Protection Scotland, national databases of all HIV patients in care in the UK up to December 2006, loss-to-follow-up patients were categorized as Transfers (subsequently received care at another UK HIV clinic) or UKLFU (no record of subsequent attendance at any HIV clinic in the UK). Logistic regression analysis was used to identify factors associated with UKLFU for those both on highly active antiretroviral therapy (HAART) and not on HAART.

Results

In total, 722 (38.8%) of 1859 patients were defined as lost to follow up. Of these, 347 (48.1%) were Transfers and 375 (51.9%), or 20.2% of all patients, were UKLFU. Overall, 11.9% of all patients receiving HAART, and 32.2% not receiving HAART were UKLFU. Among those on HAART, risk factors for UKLFU were: African heterosexual female (OR = 2.22, 95% CI: 1.11-4.56) versus white men who have sex with men; earlier year of HIV clinic registration (1997-1999 OR: 3.51, 95% CI: 1.97-6.26; 2000-02 OR: 2.49, 95% CI: 1.43-4.32 vs. 2003-2005); CD4 count of < 200 versus > 350 cells/mm3 (OR = 1.99, 95% CI:1.05-3.74); and a detectable viral load of > 400 copies/ml (OR = 5.03, 95% CI: 2.95-8.57 vs. ≤ 400 copies/ml) at last clinic visit.
Among those not receiving HAART, factors were: African heterosexual male (OR = 3.91, 95% CI: 1.77-8.64) versus white men who have sex with men; earlier HIV clinic registration (2000-2002 OR: 2.91, 95% CI: 1.77-4.78; 1997-1999: OR: 5.26, 95% CI: 2.71-10.19); and a CD4 count of < 200 cells/mm3 (OR: 3.24, 95% CI: 1.49-7.04).

Conclusions

One in five HIV-infected patients (one in three not on HAART and one in nine on HAART) from a London clinic were lost to all clinical follow up in the UK. Black African ethnicity, earlier year of clinic registration and advanced immunological suppression were the most important predictors of UKLFU. There is a need for all HIV clinics to establish systems for monitoring and tracing loss-to-follow-up patients, and to implement strategies for improving retention in care.
Literature
1.
go back to reference Antiretroviral Therapy Cohort Collaboration: Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008, 372:293–299.CrossRef Antiretroviral Therapy Cohort Collaboration: Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008, 372:293–299.CrossRef
2.
go back to reference Smit C, Geskus R, Walker S, Sabin C, Coutinho R, Porter K, Prins M, Collaboration C: Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion. AIDS 2006, 20:741–749.CrossRefPubMed Smit C, Geskus R, Walker S, Sabin C, Coutinho R, Porter K, Prins M, Collaboration C: Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion. AIDS 2006, 20:741–749.CrossRefPubMed
3.
go back to reference Kaplan JE, Hanson D, Dworkin MS, Frederick T, Bertolli J, Lindegren ML, Holmberg S, Jones JL: Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clinical Infectious Diseases 2000,30(Suppl 1):S5-S14.CrossRefPubMed Kaplan JE, Hanson D, Dworkin MS, Frederick T, Bertolli J, Lindegren ML, Holmberg S, Jones JL: Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clinical Infectious Diseases 2000,30(Suppl 1):S5-S14.CrossRefPubMed
4.
go back to reference Grinspoon S, Carr A: Cardiovascular risk and body-fat abnormalities in HIV-infected adults. New England Journal of Medicine 2005, 352:48–62.CrossRefPubMed Grinspoon S, Carr A: Cardiovascular risk and body-fat abnormalities in HIV-infected adults. New England Journal of Medicine 2005, 352:48–62.CrossRefPubMed
5.
go back to reference Hetherington S, McGuirk S, Powell G, Cutrell A, Naderer O, Spreen B, Lafon S, Pearce G, Steel H: Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clinical Therapeutics 2001, 23:1603–1614.CrossRefPubMed Hetherington S, McGuirk S, Powell G, Cutrell A, Naderer O, Spreen B, Lafon S, Pearce G, Steel H: Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clinical Therapeutics 2001, 23:1603–1614.CrossRefPubMed
6.
go back to reference Nunez M: Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. Journal of Hepatology 2006, 44:S132-S139.CrossRefPubMed Nunez M: Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. Journal of Hepatology 2006, 44:S132-S139.CrossRefPubMed
7.
go back to reference Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, Wagener MM, Singh N: Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Annals of Internal Medicine 2000, 133:21–30.PubMed Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, Wagener MM, Singh N: Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Annals of Internal Medicine 2000, 133:21–30.PubMed
8.
go back to reference Low-Beer S, Yip B, O'Shaughnessy MV, Hogg RS, Montaner JS: Adherence to triple therapy and viral load response. Journal of Acquired Immune Deficiency Syndromes: JAIDS 2000, 23:360–361.PubMed Low-Beer S, Yip B, O'Shaughnessy MV, Hogg RS, Montaner JS: Adherence to triple therapy and viral load response. Journal of Acquired Immune Deficiency Syndromes: JAIDS 2000, 23:360–361.PubMed
9.
go back to reference Taiwo B: Understanding transmitted HIV resistance through the experience in the USA. International Journal of Infectious Diseases 2009, 13:552–559.CrossRefPubMed Taiwo B: Understanding transmitted HIV resistance through the experience in the USA. International Journal of Infectious Diseases 2009, 13:552–559.CrossRefPubMed
10.
go back to reference Palella FJ, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, Holmberg SD, Investigators HIVOS: Mortality in the Highly Active Antiretroviral Therapy Era: Changing Causes of Death and Disease in the HIV Outpatient Study. JAIDS Journal of Acquired Immune Deficiency Syndromes September 2006, 43:27–34.CrossRef Palella FJ, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, Holmberg SD, Investigators HIVOS: Mortality in the Highly Active Antiretroviral Therapy Era: Changing Causes of Death and Disease in the HIV Outpatient Study. JAIDS Journal of Acquired Immune Deficiency Syndromes September 2006, 43:27–34.CrossRef
11.
go back to reference Jutte A, Schwenk A, Franzen C, Romer K, Diet F, Diehl V, Fatkenheuer G, Salzberger B: Increasing morbidity from myocardial infarction during HIV protease inhibitor treatment? AIDS 1999, 13:1796–1797.CrossRefPubMed Jutte A, Schwenk A, Franzen C, Romer K, Diet F, Diehl V, Fatkenheuer G, Salzberger B: Increasing morbidity from myocardial infarction during HIV protease inhibitor treatment? AIDS 1999, 13:1796–1797.CrossRefPubMed
12.
go back to reference D. A. D. Study Group, Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, Dabis F, De Wit S, Law M, D'Arminio Monforte A, Friis-Møller N, Kirk O, Pradier C, Weller I, Phillips AN, Lundgren JD: Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008, 371:1417–1426.CrossRefPubMed D. A. D. Study Group, Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, Dabis F, De Wit S, Law M, D'Arminio Monforte A, Friis-Møller N, Kirk O, Pradier C, Weller I, Phillips AN, Lundgren JD: Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008, 371:1417–1426.CrossRefPubMed
13.
go back to reference British HIV Association: Standards for HIV Clinical Care. 2007. British HIV Association: Standards for HIV Clinical Care. 2007.
14.
go back to reference Perez-Hoyos S, Rodriguez-Arenas MA, Garcia de la Hera M, Iribarren JA, Moreno S, Viciana P, Pena A, Gomez Sirvent JL, Saumoy M, Lacruz J, Padilla S, Oteo JA, Asencio R, del Amo J: Progression to AIDS and death and response to HAART in men and women from a multicenter hospital-based cohort. Journal of Women's Health 2007, 16:1052–1061.CrossRefPubMed Perez-Hoyos S, Rodriguez-Arenas MA, Garcia de la Hera M, Iribarren JA, Moreno S, Viciana P, Pena A, Gomez Sirvent JL, Saumoy M, Lacruz J, Padilla S, Oteo JA, Asencio R, del Amo J: Progression to AIDS and death and response to HAART in men and women from a multicenter hospital-based cohort. Journal of Women's Health 2007, 16:1052–1061.CrossRefPubMed
15.
go back to reference Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, Justice AC, Hogg RS, Deeks SG, Eron JJ, Brooks JT, Rourke SB, Gill MJ, Bosch RJ, Martin JN, Klein MB, Jacobsen LP, Rodriguez B, Sterling TR, Kirk GD, Napravnik S, Rachlis AR, Clazavara LM, Hoberg MA, Silverberg MJ, Gebo KA, Goedert JJ, Benson CA, Collier AC, Van Rompaey SE, Crane HM, McKaig RG, Lau B, Freemand AM, Moore RD, NA-ACCORD Investigators: Effect of early versus deferred antiretroviral therapy for HIV on survival. New England Journal of Medicine 2009, 360:1815–1826.CrossRefPubMed Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, Justice AC, Hogg RS, Deeks SG, Eron JJ, Brooks JT, Rourke SB, Gill MJ, Bosch RJ, Martin JN, Klein MB, Jacobsen LP, Rodriguez B, Sterling TR, Kirk GD, Napravnik S, Rachlis AR, Clazavara LM, Hoberg MA, Silverberg MJ, Gebo KA, Goedert JJ, Benson CA, Collier AC, Van Rompaey SE, Crane HM, McKaig RG, Lau B, Freemand AM, Moore RD, NA-ACCORD Investigators: Effect of early versus deferred antiretroviral therapy for HIV on survival. New England Journal of Medicine 2009, 360:1815–1826.CrossRefPubMed
16.
go back to reference Yu JK, Chen SC, Wang KY, Chang CS, Makombe SD, Schouten EJ, Harries AD: True outcomes for patients on antiretroviral therapy who are "lost to follow-up" in Malawi. Bulletin of the World Health Organization 2007, 85:550–554.CrossRefPubMed Yu JK, Chen SC, Wang KY, Chang CS, Makombe SD, Schouten EJ, Harries AD: True outcomes for patients on antiretroviral therapy who are "lost to follow-up" in Malawi. Bulletin of the World Health Organization 2007, 85:550–554.CrossRefPubMed
17.
go back to reference Karcher H, Omondi A, Odera J, Kunz A, Harms G: Risk factors for treatment denial and loss to follow-up in an antiretroviral treatment cohort in Kenya. Tropical Medicine & International Health 2007, 12:687–694.CrossRef Karcher H, Omondi A, Odera J, Kunz A, Harms G: Risk factors for treatment denial and loss to follow-up in an antiretroviral treatment cohort in Kenya. Tropical Medicine & International Health 2007, 12:687–694.CrossRef
18.
go back to reference Dalal RP, Macphail C, Mqhayi M, Wing J, Feldman C, Chersich MF, Venter WD: Characteristics and outcomes of adult patients lost to follow-up at an antiretroviral treatment clinic in johannesburg, South Africa. Journal of Acquired Immune Deficiency Syndromes: JAIDS 2008, 47:101–107.CrossRefPubMed Dalal RP, Macphail C, Mqhayi M, Wing J, Feldman C, Chersich MF, Venter WD: Characteristics and outcomes of adult patients lost to follow-up at an antiretroviral treatment clinic in johannesburg, South Africa. Journal of Acquired Immune Deficiency Syndromes: JAIDS 2008, 47:101–107.CrossRefPubMed
19.
go back to reference Ioannidis JP, Taha TE, Kumwenda N, Broadhead R, Mtimavalye L, Miotti P, Yellin F, Contopoulos-Ioannidis DG, Biggar RJ: Predictors and impact of losses to follow-up in an HIV-1 perinatal transmission cohort in Malawi. International Journal of Epidemiology 1999, 28:769–775.CrossRefPubMed Ioannidis JP, Taha TE, Kumwenda N, Broadhead R, Mtimavalye L, Miotti P, Yellin F, Contopoulos-Ioannidis DG, Biggar RJ: Predictors and impact of losses to follow-up in an HIV-1 perinatal transmission cohort in Malawi. International Journal of Epidemiology 1999, 28:769–775.CrossRefPubMed
20.
go back to reference Rosen S, Fox MP, Gill CJ: Patient Retention in Antiretroviral Therapy Programs in Sub-Saharan Africa: A Systematic Review. PLoS Medicine 2007, 4:e298.CrossRefPubMed Rosen S, Fox MP, Gill CJ: Patient Retention in Antiretroviral Therapy Programs in Sub-Saharan Africa: A Systematic Review. PLoS Medicine 2007, 4:e298.CrossRefPubMed
21.
go back to reference Lanoy E, Mary-Krause M, Tattevin P, Dray-Spira R, Duvivier C, Fischer P, Obadia Y, Lert F, Costagliola D, Clinical Epidemiology Group of French Hospital Database on HIVI: Predictors identified for losses to follow-up among HIV-seropositive patients. Journal of Clinical Epidemiology 2006, 59:829–835.CrossRefPubMed Lanoy E, Mary-Krause M, Tattevin P, Dray-Spira R, Duvivier C, Fischer P, Obadia Y, Lert F, Costagliola D, Clinical Epidemiology Group of French Hospital Database on HIVI: Predictors identified for losses to follow-up among HIV-seropositive patients. Journal of Clinical Epidemiology 2006, 59:829–835.CrossRefPubMed
22.
go back to reference Coleman S, Boehmer U, Kanaya F, Grasso C, Tan J, Bradford J: Retention challenges for a community-based HIV primary care clinic and implications for intervention. AIDS Patient Care STDS 2007, 21:691–701.CrossRefPubMed Coleman S, Boehmer U, Kanaya F, Grasso C, Tan J, Bradford J: Retention challenges for a community-based HIV primary care clinic and implications for intervention. AIDS Patient Care STDS 2007, 21:691–701.CrossRefPubMed
23.
go back to reference Lebouche B, Yazdanpanah Y, Gerard Y, Sissoko D, Ajana F, Alcaraz I, Boitte P, Cadore B, Mouton Y: Incidence rate and risk factors for loss to follow-up in a French clinical cohort of HIV-infected patients from January 1985 to January 1998. HIV Medicine 2006, 7:140–145.CrossRefPubMed Lebouche B, Yazdanpanah Y, Gerard Y, Sissoko D, Ajana F, Alcaraz I, Boitte P, Cadore B, Mouton Y: Incidence rate and risk factors for loss to follow-up in a French clinical cohort of HIV-infected patients from January 1985 to January 1998. HIV Medicine 2006, 7:140–145.CrossRefPubMed
24.
go back to reference Mocroft A, Kirk O, Aldins P, Chies A, Blaxhult A, Chentsova N, Vetter N, Dabis F, Gatell J, Lundgren LD, group ftEs: Loss to follow-up in an international, multicentre observational study. HIV Medicine 2008, 9:261–269.CrossRefPubMed Mocroft A, Kirk O, Aldins P, Chies A, Blaxhult A, Chentsova N, Vetter N, Dabis F, Gatell J, Lundgren LD, group ftEs: Loss to follow-up in an international, multicentre observational study. HIV Medicine 2008, 9:261–269.CrossRefPubMed
25.
go back to reference Cohen CJ, Iwane MK, Palensky JB, Levin DL, Meagher KJ, Frost KR, Mayer KH: A national HIV community cohort: design, baseline, and follow-up of the AmFAR Observational Database. American Foundation for AIDS Research Community-Based Clinical Trials Network. Journal of Clinical Epidemiology 1998, 51:779–793.CrossRefPubMed Cohen CJ, Iwane MK, Palensky JB, Levin DL, Meagher KJ, Frost KR, Mayer KH: A national HIV community cohort: design, baseline, and follow-up of the AmFAR Observational Database. American Foundation for AIDS Research Community-Based Clinical Trials Network. Journal of Clinical Epidemiology 1998, 51:779–793.CrossRefPubMed
26.
go back to reference Arici C, Ripamonti D, Maggiolo F, Rizzi M, Finazzi MG, Pezzotti P, Suter F: Factors associated with the failure of HIV-positive persons to return for scheduled medical visits. HIV Clinical Trials 2002, 3:52–57.CrossRefPubMed Arici C, Ripamonti D, Maggiolo F, Rizzi M, Finazzi MG, Pezzotti P, Suter F: Factors associated with the failure of HIV-positive persons to return for scheduled medical visits. HIV Clinical Trials 2002, 3:52–57.CrossRefPubMed
27.
go back to reference Brown DM, Thorne JE, Foster GL, Duncan JL, Brune LM, Munana A, Meinert CL, Jabs DA: Factors affecting attrition in a longitudinal study of patients with AIDS. AIDS Care 2006, 18:821–829.CrossRefPubMed Brown DM, Thorne JE, Foster GL, Duncan JL, Brune LM, Munana A, Meinert CL, Jabs DA: Factors affecting attrition in a longitudinal study of patients with AIDS. AIDS Care 2006, 18:821–829.CrossRefPubMed
28.
go back to reference Hessol NA, Schneider M, Greenblatt RM, Bacon M, Barranday Y, Holman S, Robison E, Williams C, Cohen M, Weber K: Retention of Women Enrolled in a Prospective Study of Human Immunodeficiency Virus Infection: Impact of Race, Unstable Housing, and Use of Human Immunodeficiency Virus Therapy. American Journal of Epidemiology 2001, 154:563–573.CrossRefPubMed Hessol NA, Schneider M, Greenblatt RM, Bacon M, Barranday Y, Holman S, Robison E, Williams C, Cohen M, Weber K: Retention of Women Enrolled in a Prospective Study of Human Immunodeficiency Virus Infection: Impact of Race, Unstable Housing, and Use of Human Immunodeficiency Virus Therapy. American Journal of Epidemiology 2001, 154:563–573.CrossRefPubMed
29.
go back to reference Dudley J, Jin S, Hoover D, Metz S, Thackeray R, Chmiel J: The Multicenter AIDS Cohort Study: Retention after 9 1/2 Years. American Journal of Epidemiology 1995, 142:323–330.PubMed Dudley J, Jin S, Hoover D, Metz S, Thackeray R, Chmiel J: The Multicenter AIDS Cohort Study: Retention after 9 1/2 Years. American Journal of Epidemiology 1995, 142:323–330.PubMed
30.
go back to reference South East London Health Protection Unit: The epidemiology of HIV in South East London 1995–2005. London; 2007. South East London Health Protection Unit: The epidemiology of HIV in South East London 1995–2005. London; 2007.
31.
go back to reference Mortimer JY, Salathiel JA: 'Soundex' codes of surnames provide confidentiality and accuracy in a national HIV database. Communicable Disease Report CDR Review 1995, 5:R183–186.PubMed Mortimer JY, Salathiel JA: 'Soundex' codes of surnames provide confidentiality and accuracy in a national HIV database. Communicable Disease Report CDR Review 1995, 5:R183–186.PubMed
32.
go back to reference Bassett IV, Regan S, Chetty S, Giddy J, Uhler LM, Holst H, Ross D, Katz JN, Walensky RP, Freedberg KA, Losina E: Who starts antiretroviral therapy in Durban, South Africa?...not everyone who should. AIDS 2010,24(Suppl 1):S37-S44.CrossRefPubMed Bassett IV, Regan S, Chetty S, Giddy J, Uhler LM, Holst H, Ross D, Katz JN, Walensky RP, Freedberg KA, Losina E: Who starts antiretroviral therapy in Durban, South Africa?...not everyone who should. AIDS 2010,24(Suppl 1):S37-S44.CrossRefPubMed
33.
go back to reference Braitstein P, Boulle A, Nash D, Brinkhof MW, Dabis F, Laurent C, Schechter M, Tuboi SH, Sprinz E, Miotti P, Hosseinpour M, May M, Egger M, Bangsberg DR, Low L, The Antiretrovial Therapy In Lower Income Countries (ART-LINC) Study Group: Gender and the use of antiretroviral treatment in resource-constrained settings: findings from a multicenter collaboration. Journal of Women's Health 2008, 17:47–55.CrossRefPubMed Braitstein P, Boulle A, Nash D, Brinkhof MW, Dabis F, Laurent C, Schechter M, Tuboi SH, Sprinz E, Miotti P, Hosseinpour M, May M, Egger M, Bangsberg DR, Low L, The Antiretrovial Therapy In Lower Income Countries (ART-LINC) Study Group: Gender and the use of antiretroviral treatment in resource-constrained settings: findings from a multicenter collaboration. Journal of Women's Health 2008, 17:47–55.CrossRefPubMed
34.
go back to reference Muula AS, Ngulube TJ, Siziya S, Makupe CM, Umar E, Prozesky HW, Wiysonge CS, Mataya RH: Gender distribution of adult patients on highly active antiretroviral therapy (HAART) in Southern Africa: a systematic review. BMC Public Health 2007, 7:63.CrossRefPubMed Muula AS, Ngulube TJ, Siziya S, Makupe CM, Umar E, Prozesky HW, Wiysonge CS, Mataya RH: Gender distribution of adult patients on highly active antiretroviral therapy (HAART) in Southern Africa: a systematic review. BMC Public Health 2007, 7:63.CrossRefPubMed
Metadata
Title
High rate of loss to clinical follow up among African HIV-infected patients attending a London clinic: a retrospective analysis of a clinical cohort
Authors
Sarah M Gerver
Tim R Chadborn
Fowzia Ibrahim
Bela Vatsa
Valerie C Delpech
Philippa J Easterbrook
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Journal of the International AIDS Society / Issue 1/2010
Electronic ISSN: 1758-2652
DOI
https://doi.org/10.1186/1758-2652-13-29

Other articles of this Issue 1/2010

Journal of the International AIDS Society 1/2010 Go to the issue